The Effect of Biomarker Use on the Speed and Duration of Clinical Trials for Cancer Drugs
Class of 2021
Class of 2021
The Oncologist, 2022, 27(10), 849-856
› 10.1093/oncolo/oyac130
Impact Factor: 5·8
Application relevance: The study showcased a novel visualization method to assess and compare whether biomarkers have an impact on the speed and duration of oncology clinical trials (across 4 indications). The novel visualization method revealed longer gaps between trial phases, later clinical trial start times, and shorter periods of concurrently run trials for drugs that used biomarkers. The study, therefore, highlights that biomarker-driven trials may impact drug approval timelines, and so these and other findings allow clinical researchers to carefully consider biomarker inclusion in their clinical development plans in oncology.